Washington - Novartis, which opened the plant the next generation of vaccines against flu in the United States on Tuesday, but it will take years before the first vaccine.The factory in Holly Springs, North Carolina, lots of dog cells used to grow flu vaccine, instead of chicken eggs are widely used today. Although the method of cells is only slightly faster, can be established from a ladder faster.
Councilors U. S. Federal Food and Drug Administration last week asked for additional safety data on other cell-based vaccines, made by a person in private ownership Body Science protein. But U.S. officials that Novartis is not the shooting as a new trial.
"I see them as completely different. The point of pushing the cell culture was to increase the capacity and potential wavelength, Dr Bruce Gellini, head of the U.S. Health and Human Services National Program Office of the vaccine, said that interviews .
HHS Novartis spent 487 million U.S. dollars to help build the facility, which was planned before the current pandemic of H1N1 swine flu.
The U.S. government is struggling enough to vaccinate Americans against H1N1. The Center for Disease Control and Prevention estimates 22 million Americans are infected, and I want to vaccinate at least 160 million people.
But just over 50 million vaccines for the H1N1 distribution.
When you and go forward in 2011, Novartis said Holly Springs plant will be able to make 50 million doses of vaccine against seasonal flu for years, and up to 150 million doses of pandemic vaccine within six months a pandemic is declared.
Assumes that the pandemic vaccine adjuvant - an additive that increases the body in response to the vaccine and lowers the dose needed.
Carriers that are not licensed for use in the United States today, mostly because of the widespread public distrust of the new vaccine ingredients.
GM Hot news
